Bavarian Nordic A/S: Bavarian Nordic Commits to Initiating P

Bavarian Nordic to initiate Phase 3 with RSV vaccine candidate in first half of 2022 subject to a successful equity capital raiseEBITDA expectations for 2021 slightly lowered, as Phase 3 preparations are

Related Keywords

United States , Canada , Denmark , Copenhagen , Køavn , United Kingdom , Paul Chaplin , Graham Morrell , Janssen Pharmaceutical Companies Of Johnson , Nordea , Company Announcement , Bavarian Nordic , Respiratory Syncytial Virus , Janssen Pharmaceutical Companies , Joint Global Coordinators , Joint Bookrunners , Vice President Investor Relations , Paddock Circle Advisors , Bavarian , Ordic , Commits , Initiating , Hase , Trial , Vaccine , Candidate , Strengthening , Capital ,